Introduction {#S1}
============

Kawasaki disease (KD) is the leading cause of acquired heart disease in children in the United States (U.S.). It is a potentially life-threatening acute vasculitis with diffuse involvement of multiple organ systems^[@R1]^ and has a predilection for the coronary arteries. In the U.S. about 5500 cases were estimated in 2009 by passive surveillance alone;^[@R2]^ and based on the system dynamics modeling simulations, there will be an average of 6200 new patients per year and a total of 161 776 individuals (half of them adults) with a history of KD by 2030.^[@R3]^ The disease is primarily associated with the East Asian populations although there has been an increase in the incidence of KD among European-Americans over the last two decades.^[@R4]^ The primary treatment of KD is the administration of intravenous immunoglobulins (IVIG) accompanied by aspirin.^[@R5]^ Approximately 15 to 25% of the cases require more than a single dose of IVIG therapy to achieve complete resolution.^[@R5]^ Furthermore, coronary artery aneurysms develop in 15-25% untreated cases compared to \<5% among those treated, although a substantially higher percentage show coronary artery dilation.^[@R5]^

KD, also known as mucocutaneous lymph node syndrome (MCLS), is considered an autoimmune disease since walls of the blood vessels are inflamed throughout the body with damage to coronary arteries likely mediated by auto-antibodies to endothelial cells (ECs).^[@R6]^ Parental KD is also considered a risk factor with the odds of KD among siblings and recurrent cases being 7 and 3 times higher among KD children and parents with history of KD, respectively compared to the general population,^[@R7]^ suggesting a genetic etiology. However, genetic studies, including genome-wide association studies (GWAS) are often inconsistent and the associations are often race or ethnicity specific. Furthermore, only few candidate gene studies, including ours have assessed the gene-IVIG nonresponse association.^[@R8]-[@R12]^ Our objective was to fine-map regions of immune-related genes using the Human ImmunoChip to validate the association of immune related genes with susceptibility to Kawasaki disease, search for novel SNPs, examine shared loci with other autoimmune diseases and perform genetic evaluation for IVIG treatment response among European American case-parent trios.

Results {#S2}
=======

The average age of the probands was 45.7 (± 32.3) months, with the average age for the responders being 44.8 (± 30.8) months and the non-responders being 46.6 (± 33.9) months. Overall, the study population consisted of 56.1% male probands, 48.1% males being responders and 64.2% being non-responders.

Susceptibility to Kawasaki disease {#S3}
----------------------------------

The Manhattan plots corresponding to the p-values for the SNPs in the transmission disequilibrium test (TDT) test are presented in [Figure 1a](#F1){ref-type="fig"} for the additive model and [Figure 1b](#F1){ref-type="fig"} for the dominant model. The Q-Q plots are illustrated in [supplementary Figure S1a and S1b](#SD1){ref-type="supplementary-material"}. The top 15 results from the FBAT analysis for the association between the SNPs and susceptibility to KD are presented in [Table 1](#T1){ref-type="table"}; upper panel for the additive model and lower panel for the dominant model (all results in [supplementary Table 1](#SD1){ref-type="supplementary-material"} and [Supplementary Figure S3](#SD1){ref-type="supplementary-material"} shows the LD plot for regions with multiple hits in chromosomes 1, 5 and 19). In the additive model, the top SNPs were predominantly located in chromosome 19, largely located in regions of galactoside 2-alpha-L-fucosyltransferase 1 (*FUT1*) gene and Ras interacting protein 1 (*RASIP1*) gene ([Table1](#T1){ref-type="table"}), but not in the region of inositol-trisphosphate 3-kinase C (*ITPKC*), another gene located on chromosome 19 that has been previously linked to KD. The topmost SNP (rs838143) and two other more common SNPs (rs838142 and rs4021), all in the untranslated region (UTR) of the *FUT1* gene, were significantly over-transmitted from the parents to KD children (p=2.70×10^-5^, 4.80×10^-5^, 1.18×10^-4^, respectively).

In the dominant model, rs9847915 in the intergenic region between *LOC730109* and Bromodomain containing 7 Pseudogene 2 (*BRD7P2*) on chromosome 3 was the topmost SNP significantly associated (p=6.81×10^-7^) with susceptibility to KD ([Table 1](#T1){ref-type="table"}, lower panel). However, association of SNPs was largely observed in genes on chromosome 1, in the region of *FCGR* gene family cluster.

IVIG response {#S4}
-------------

The Manhattan plots that summarize the associations between each SNP and response to IVIG treatments are presented in [Figure 2a](#F2){ref-type="fig"} for the additive model and [Figure 2b](#F2){ref-type="fig"} for the dominant model (Q-Q plots in [supplementary Figure S2a and S2b](#SD1){ref-type="supplementary-material"}). The top 15 associated SNPs are presented in [Table 2](#T2){ref-type="table"}, upper panel for additive model and lower panel for dominant model (all results in [supplementary Table 2](#SD1){ref-type="supplementary-material"} and [Supplementary Figure S3](#SD1){ref-type="supplementary-material"} shows the LD plot for regions with multiple hits in chromosomes 6 and 16). In the additive model, intergenic variant rs1200332 between Bromodomain adjacent to zinc finger domain, 1A (*BAZ1A*) and *C14orf19* genes on chromosome 14 was the topmost significantly associated SNP with response to IVIG treatment. The odds of not responding to IVIG treatment was 5 times higher in those with the minor allele T (OR-nonresponders: 5.49, p=1.40×10^-4^) compared to the wild-type C allele. On the other hand, individuals with a minor allele at SNPs rs6017164, rs72945401, rs7579420, rs7163190, rs3134926, rs3777914, rs1883137, and rs11641163 had higher odds of responding to IVIG and most of these responders had minor allele frequency (MAF) closer to the reported frequency for HapMap Caucasians ([Table 2](#T2){ref-type="table"}). Several SNPs on chromosome 6 were also found to be significantly associated with IVIG responsiveness in or around G-protein coupled receptor-6 (*GPR6*)/Wiskott-Aldrich syndrome protein (WASP)-family, member 1 (*WASF1*), protein reversionless 3-like (*REV3L*), neurogenic locus notch homolog protein 4 (*NOTCH4*)/ *C6orf10*, and tumor necrosis factor receptor family 3 interacting protein 2 (*TRAF3IP2*) genes.

The top SNPs associated with response to IVIG treatment using the dominant model were predominantly located on chromosome 16 and several of them were in linkage disequilibrium ([Table 2](#T2){ref-type="table"}, lower panel). The top most significant SNP was rs4889606, located in the intronic region of the syntaxin 1B (*STX1B*) gene on chromosome 16 and in linkage disequilibrium with rs9926533. This SNP was associated with a lower odds of IVIG non-response among those carrying the minor allele G (OR-nonresponders: 0.13, p=6.95×10^-5^) compared to the wild-type "A" allele. Other SNPs located on chromosome 16 were found either in the intronic or intergenic regions of SET domain-containing protein 1A (*SETD1A*), F-box and Leucine-rich repeat protein 19 (*FBXL19*), cardiotrophin-1 (*CTF1*)/*LOC283932*, and syntaxin 1B and 4 (*STX1B*/*STX4*) or *STX4*/ zinc finger protein 668 (*ZNF668*) genes and all were associated with higher odds of response to IVIG treatment.

Discussions {#S5}
===========

In the present study, we evaluated the genetic association of susceptibility to KD and IVIG treatment response using the ImmunoChip in homogenous European-American case-parent trios. While the sample-size was relatively small, several SNPs from previous studies were replicated in our family-based study, strengthening our results. Furthermore, these replicated SNPs along with few of the top significant SNPs in our current study were found to be expression quantitative trait loci (eQTLs) for specific genes and are therefore more likely to play a functional role in the regulation of gene and expression and subsequent immune response to KD. Consequently, we discuss these SNPs in addition to some of the SNPs that were highly significantly in our study and have shown previous associations with autoimmune diseases.

Two SNPs, rs2857151 in the intergenic region of the human leucocyte antigen class II histocompatibility antigen, DQ beta 2 chain and DO beta (*HLA-DQB2* and *HLA-DOB*), and rs4813003 downstream of TNF receptor superfamily member 5 (TNFRSF5) or B-cell associated molecule CD40 (*CD40*) gene that were previously reported in GWAS to be associated with KD were replicated ([Table 3](#T3){ref-type="table"}).^[@R13]^ SNP rs2857151 was shown to be an eQTL for several of the HLA genes, namely, *HLA-DOB*, -*DRB1*, -*DRB5*, -*DQA1*, -*DQA2*, and transporter 2, ATP-binding cassette, sub-family B (*TAP2*).^[@R14]^ SNP rs4813003 was shown to be an eQTL for the CD40 gene.^[@R14],\ [@R15]^ SNP rs2857151 in combination with rs4813003 and another locus in a 3-locus model were previously shown to confer the highest risk for KD whereas the same SNP with rs1801274 was shown to confer the highest risk for CALs.^[@R13]^ The compound effect was hypothesized to provide evidence for the additive effect of these loci on KD. SNPs within the *TAP2* gene have also been associated with autoimmune diseases like rheumatoid arthritis (RA), ankylosing spondylitis and multiple sclerosis and the TAP2 proteins are known to play an important role in antigen presentation.^[@R16]-[@R19]^ SNP rs4813003 is located in the intergenic region between the *CD40* and the cadherin 22 (*CDH22*) genes. CD40 is a receptor protein which is part of the TNFR superfamily and is expressed on B cells, monocytes, dendritic cells, ECs and epithelial cells.^[@R20]^ It interacts with the CD40 ligand on the T-helper cells and mediates immune and inflammatory responses. CD40 was also recently observed to facilitate damage to ECs through an inflammatory response mounted via activated platelets and the expression of adhesion molecules.^[@R20]^ On the other hand, CDH22 is a type of cadherin, part of a superfamily of transmembrane proteins, and is known to mediate cell-to-cell adhesion in a calcium dependent manner. Altered expression of CDH22 has been previously associated with cell proliferation, invasiveness and metastasis in certain cancers.^[@R21]^

Previously, we had independently shown that rs1801274 in *FCGR2A* gene is associated with KD susceptibility in European-Americans,^[@R9],\ [@R11]^ confirming similar findings from a GWAS study.^[@R22]^ Multiple variants in the *FCGR* gene family cluster within the ImmunoChip were also associated with KD susceptibility in our TDT analysis with a dominant inheritance, with SNPs in both the intronic and intergenic regions associated with KD susceptibility. This gene region is consistent with our previous studies of KD.^[@R9]-[@R11]^ These findings are encouraging, specifically since results from several GWAS studies have been replicated in only few studies using independent cohorts.^[@R23],\ [@R24]^ Polymorphisms and copy number variation of *FCGR* genes are also associated with susceptibility for autoimmune diseases such as RA and systemic lupus erythematosus (SLE). Accordingly, an intersection could potentially exist between KD and other autoimmune disorders.

While the function of several genes in [Table 1](#T1){ref-type="table"} is unknown or unconfirmed, few (*FUT1, RASIP1,* and *BRD7P2*) are noteworthy and could have potential biological mechanism in KD pathway. The SNPs significantly associated with KD in the additive model were located in the 3′UTR region of the *FUT1* gene, the intronic region of the *RASIP1* gene and the intergenic region of the *BRD7P2* gene. *FUT1* encodes the galactoside 2-alpha-L-fucosyltransferase 1 enzyme that is involved in the formation of the H antigen on erythroid cells, regulating the expression of ABO antigens.^[@R25],\ [@R26]^ FUT1 plays a major role in the pathogenesis of RA and is involved in angiogenesis, cell adhesion and cell proliferation of various inflammatory cells.^[@R27]^ This role is further supported by experiments showing inactivation of *FUT1* using short-interfering RNA where reduction in cell proliferation and tumor growth were observed as well as migration of ECs and integration with the extracellular matrix (ECM).^[@R28]-[@R30]^ Macrophages are also reported to modulate the expression of *FUT1* and *FUT2* through the interleukin-6 (IL-6) signaling pathway in epithelial cells of the endometrium to enable implantation of the embryo and increased levels of macrophages are potentially associated with inflammatory response.^[@R31]^ The three SNPs from our study are located in the 3′ UTR of *FUT1*, and interestingly MAF for all three was higher in HapMap Asians compared to Caucasians but the same allele was the wild-type allele in Yoruban Africans. While the functions of these SNPs are not known, future studies could evaluate the potential binding sites of miRNAs in the 3′ UTR in relation to these variants. The *RASIP1* gene encodes the RASIP1 protein that has been associated with tubulogenesis and angiogenesis in as early as the embryonic stage and is specific to the endothelium.^[@R32]^ Lumen formation via RASIP1 occurs through the regulation of the Rho family of monomeric G proteins, requiring the suppression of RhoA and activation of Cdc42 and Rac1 proteins.^[@R33]^ RASIP1 deficient vessels are shown to collapse as EC adhesion to the ECM is lacking.^[@R33]^ RASIP1 variants have been associated with early microvascular disease, which is a predictor of incident cardiovascular disease, and Crohn\'s disease in conjunction with FUT2.^[@R34],\ [@R35]^ Thus it may play a more important role in the pathogenesis of both KD and CALs. SNP rs9847915 in the *BRD7P2* gene was associated with susceptibility to KD in our study; the MAF for this SNP is lowest among Africans but similar for Asians and Caucasians from HAPMAP. This gene has been associated with phenotypes such as Behcet\'s syndrome which also involves systemic vasculitis of small vessels with an auto-immune component.^[@R36]^

To date, IVIG responsiveness has not yet been evaluated using large-scale genotyping arrays. Even with a smaller sample-size, several genes (*BAZ1A, GPR6, TRAF3IP2, REV3L, STX1B, STX4,* and *CTF1*), listed in [Table 2](#T2){ref-type="table"}, are noteworthy as working mechanisms of IVIG therapy have yet to be fully elucidated. Additionally, SNP rs1200332 was shown to be an eQTL for chromosome 14 open reading frames 10 and 24 (*C14orf10* and *C14orf24*) and SNP rs10871454 as an eQTL for *ZNF668*, *STX4* and *SETD1A* among others.^[@R14]^

In the additive model, SNPs located in the intergenic region of the *BAZ1A* gene, the 3′UTR and intergenic regions of the *GPR6* gene and the intronic regions of the *TRAF3IP2* gene were significantly associated with IVIG responsiveness. The SNP rs1200332 in the intergenic region of *BAZ1A* and *C14orf19* genes has been associated with Crohn\'s disease, an autoimmune disease, in Puerto Ricans.^[@R37]^ The MAF of rs1200332 is higher among Africans but lower and similar across Caucasians and Asians in HAPMAP. The *BAZ1A* gene encodes a subunit of the adenosine triphosphate (ATP)-dependent chromatin assembly factor (ACF) which is part of the chromatic remodeling complex and is involved in DNA damage response and repair.^[@R38]^ The *GPR6* gene encodes the GPR6 protein that is expressed on vascular smooth muscles cells and ECs and is an orphan GPCR modulated by sphingosine-1 phosphate (S1P), an important regulator in the vascular system.^[@R39]^ The *TRAF3IP2* gene codes for the TRAF3-interacting protein 2, also known as activator 1 (Act1), that acts as a signaling adaptor in IL-17 mediated cellular immune responses through nuclear factor κ-B (NF- κB) activation or as a negative regulator by inhibiting CD40 and B-cell activating factor receptor (BAFFR) mediated signaling.^[@R40]^ *TRAF3IP2* has also been associated with auto-immune disorders like psoriasis and SLE and is speculated to bring about loss of the negative regulatory role of Act1 in SLE resulting in B-cell hyperplasia and enhanced survival of autoreactive B-cells.^[@R40]^

In the dominant model, most SNPs associated were in chromosome 16 in the intronic and intergenic regions of the *STX* gene family; the top SNP rs4889606 in the *STX1B* gene having the lowest MAF among Africans but the same minor allele being the wild-type allele among Asians from HAPMAP. In general, the interaction of syntaxin with synaptotagmin results in fusion of the vesicular and plasma membranes and subsequent exocytosis.^[@R41]^ Smirnova et. al. speculated that syntaxin may be involved in the Lambert-Eaton syndrome, an autoimmune disorder associated with some small cell lung cancers resulting in antibodies against synaptotagmin and calcium channels.^[@R42]^ Several SNPs within the intronic and intergenic region of the *STX4* gene were associated with increased IVIG response. The *STX4* gene encodes for STX4 which is also part of the syntaxin family of membrane integrated proteins.^[@R43]^ STX4 plays an important role in the regulation of secretions from various immune cells including neutrophils, macrophages and eosinophils.^[@R44]^ The addition of short interfering RNAs against STX4 has been shown to reduce IgE antibody exocytosis from plasma cells from several cell lines.^[@R43]^ It was additionally shown that STX4 knock-down results in reduced secretion of tumor necrosis factor-α from macrophages.^[@R44]^ SNPs in the intergenic region of the *CTF1* gene were also significantly associated with IVIG responsiveness. The *CTF1* gene encodes for the CTF1 protein which is part of the IL-6 family and is involved in cell proliferation, cell migration and collagen production. CTF1 is largely localized to the ECs and vascular smooth muscle cells with genetic variations in the gene associated with dilated cardiomyopathy or hypertension related left ventricular hypertrophy.^[@R45]-[@R47]^ CTF1 has been shown to have both beneficial as well as detrimental effects based on which signaling pathway is induced since it has been associated with wound healing in myocardial infarction and prevention of apoptosis due to hypoxia as well as plaque instability and pathophysiology of atherosclerosis.^[@R48],\ [@R49]^ The role of all these genes in IVIG response could potentially be mediated through various immunity signaling pathways.

There are several strengths to our study. Sample-size was relatively small in our study and thus the findings in our study are preliminary; however, considering that KD is rare (13.7 per 100,000 among whites \< 5 years)^[@R4]^ and only 15 to 25% do not respond to IVIG treatment, the difficulty in assembly of trios for this study should be appreciable. The trio-based family analysis using TDT is robust to factors like confounding and variance inflation which enabled us to confirm and replicate previous findings related to KD susceptibility despite the small sample size of our study. Additionally, we determined ethnicity based on ancestry informative markers (AIMs) and performed the analysis in confirmed European-Americans, accounting for population stratification and thus ensuring a homogenous population.

Our study is not without limitations. Of note, we included equal number of IVIG responders and non-responders for the TDT analysis; thus, some of the findings could be biased towards less frequent IVIG responders in the population, as they were preferentially included in the analyses. The ImmunoChip largely includes genes that were associated with several autoimmune disorders and was therefore ideal for testing genetic associations with KD but does not represent the whole spectrum of SNPs and genes that may be involved in immune response. As a result, the density of markers found on the ImmunoChip is not as high as opposed to fine mapping of gene regions and thus the SNPs associated in our study may be tagging one or more SNPs in LD and/or possibly the true causal variants. Lastly, we largely describe SNPs in the UTR and intronic regions although we acknowledge that variants from other parts of the region can be functional and related to distant genes.^[@R50]^ And even though we include discussion of certain SNPs as eQTLs for some genes, we recognize that we were limited by the annotations provided by the ImmunoChip consortium and express caution in interpreting these results since certain eQTLs are reported in relation to specific cells and therefore may not be generalizable or applicable in the context of KD.

In the current study, we took a hypothesis-free agnostic approach to show that several SNPs in immune related genes included in the ImmunoChip are associated with susceptibility to KD and IVIG response. Some of these genetic associations have not yet been reported and can be potentially involved in KD pathogenesis while some of these genes are known to be in the pathway of other known autoimmune diseases. Future studies are therefore needed to replicate these findings and further fine-mapping is required to identify biologically causal SNPs as well as their functions in relation to either KD susceptibility or IVIG response mechanisms.

Methods {#S6}
=======

Study population {#S7}
----------------

The current study included 112 case-parent trios of European-American descent from a retrospective cohort of KD. The study cohort has been described in detail previously.^[@R11]^ Briefly, the probands (55 IVIG responders and 55 non-responders) were identified through clinical or hospital databases and then cross-referenced with the echocardiography databases of the respective heart centers. The probands were enrolled from children\'s hospitals at three locations: Seattle, WA; Oakland, CA; and Salt Lake City, UT. The study was approved by the Institutional Review Board at each of the participating institution and informed consent was obtained from the parents.

Clinical Outcomes {#S8}
-----------------

### Kawasaki disease {#S9}

Kawasaki disease was defined based on the guidelines recommended by the American Heart Association (AHA) and the American Academy of Pediatrics (AAP).^[@R10],\ [@R51]^ The standard epidemiological criteria require the presence of fever for ≥ 5 days and at least 4 of 5 clinical features to make the diagnosis of KD. Participants in our study were included based on the initial criteria but we also included those with at least 2 clinical features accompanied by coronary artery involvement.

### Response to IVIG {#S10}

The treatment of Kawasaki disease included administration of an intravenous infusion of Immunoglobulin at 2 g/kg along with Aspirin within 10 days of the onset of fever. Nonresponse, or refractoriness to the initial IVIG therapy was characterized by the presence of persistent fever (≥ 38 °C) at ≥ 36 hours or recurrence of fever (≥ 38 °C) at ≥ 36 hours.^[@R51]^

DNA extraction, genotyping and quality control {#S11}
----------------------------------------------

As previously described, genomic DNA was extracted from blood or saliva samples obtained from the probands and their biological parents using the Versagene DNA purification kit (Gentra Systems, Minneapolis MN).^[@R11]^ The PicoGreen assay for double stranded DNA was used for quantification and the final concentration was adjusted to 100ng/μl in Tris-EDTA.

Genotyping was performed using the ImmunoChip, an iSelect HD custom genotyping array (Illumina, San Diego CA), developed by the ImmunoChip Consortium.^[@R52]^ The ImmunoChip contains 195,806 SNPs and 718 small insertions-deletions, of which 5,001 are non-synonymous coding, 1,926 are synonymous coding, 4,065 located in the untranslated region (UTR), and the rest fall either in the intronic, intergenic or undefined regions. The loci were selected on the basis of their associations with autoimmune or inflammatory diseases and ImmunoChip was designed using early 1000 Genome Pilot data (February 2010 release).^[@R52],\ [@R53]^

For genotype calling purposes, the data was analyzed using the Genome Studio Genotyping Module (Illumina, San Diego CA) using the NCBI build 36 (hg18) map. The normalized probe intensities were extracted for all samples that passed standard laboratory quality-control (QC) thresholds. Further QC included examining the SNPs for missingness by SNP and by individual, deviations from Hardy-Weinberg Equilibrium (HWE) at p-value \<0.001 and minor allele frequencies \< 0.05. Of a total 195,806 SNPs, there were 191,475 in the autosomal chromosomes. A total of 36 individuals were excluded as a result of missing \> 10% genotypes data, of which 3 were probands and the rest were parents. Similarly, 16,220 SNPs were excluded since they were missing genotype data in \> 10% of the sample population. Additionally, deviation from HWE was observed in 477 SNPs and 68,761 SNPs had minor allele frequency \< 0.05 and therefore excluded from the analysis.

Statistical methods {#S12}
-------------------

TDT was employed to assess susceptibility to KD using family-based association test (FBAT), as described previously.^[@R11]^ Briefly, parent-child trios were evaluated for differential transmission of alleles from heterozygous parents to the affected child. Single marker analysis was conducted to test the association under the null hypothesis of no linkage and no association using both additive and dominant genetic models. The direction and frequency of transmission is provided through the Z statistic and p-values.

The genetic association of response to IVIG treatment was assessed by implementing a case-control approach (responders versus non-responders) and performing logistic regression analyses adjusting for age and first two principal components, using both additive and dominant models in PLINK (v1.07).^[@R54]^ European-American ancestry of all parents and probands was confirmed using 155 AIMs in EIGENSTRAT.^[@R10],\ [@R11],\ [@R55]^ Quantile-quantile (Q-Q) and Manhattan plots, based on p-values, were created using SAS 9.3 (SAS Institute Inc., Cary, NC) to evaluate deviations of the observed test statistics distribution from the expected one and to visualize the association results, respectively.

Supplementary Figures {#S13}
=====================

[**Figure S1**](#SD1){ref-type="supplementary-material"} Quantile-quantile (QQ) plot of the association between SNPs and susceptibility to Kawasaki disease using a) additive model and b) dominant model

[**Figure S2**](#SD1){ref-type="supplementary-material"} Quantile-quantile (QQ) plot of the association between SNPs and IVIG response to Kawasaki disease using a) additive model and b) dominant model

[**Figure S3**](#SD1){ref-type="supplementary-material"} Locus-specific (-log~10~(p-value)) regional association plots for KD susceptibility (additive models in chromosomes 5 and 19 and dominant models in chromosome 1) and response to IVIG treatment (additive model in chrosmosome 6 and dominant model in chromosome 16) usin NCBI build 37, hg19. The diamond in purple indicates the most strongly associated signal. Estimated recombination rates are plotted in light blue graphical lines (labeled in right y-axis) to reflect the local LD structure from the HapMap population. The spectrum of colors indicates LD of each SNP with the most strongly associated signal (r^2^ values from HapMap where bright red indicates highly correlated, dark blue indicates weakly correlated and grey indicates missing r^2^ values).

Supplementary Material {#S14}
======================

The parent study and this genetic sub-study conformed to the procedures for informed consent (parental permission) approved by institutional review boards at all sponsoring organizations and to human-experimentation guidelines set forth by the United States Department of Health and Human Services. We thank the participating patients and their parents. We also thank investigators (Dr.Neil E Bowles at Department of Pediatrics, University of Utah, Salt Lake City, UT; Dr. Hitendra Patel at Children\'s Hospital of Oakland, Oakland, CA), pediatricians and staffs of the participating clinics. This study was supported by grants NHLBI-R21-HL90558 & The American Heart Association.

![Manhattan plot of the association between SNPs in the ImmunoChip and susceptibility to Kawasaki Disease using the transmission disequilibrium test (TDT) in a) additive model and b) dominant model](nihms608867f1){#F1}

![Manhattan plot of the association between SNPs in the ImmunoChip and response to IVIG treatment using logistic regression in a) additive model and b) dominant model](nihms608867f2){#F2}

###### Top 15 significant SNPs associated with susceptibility to Kawasaki disease using the a) additive model and b) dominant model in FBAT

  CHR   SNP                  Position    Gene Symbol                 Gene Location   Risk[\*](#TFN1){ref-type="table-fn"} allele   MAF HAPMAP/1000 Genomes   p-Value
  ----- -------------------- ----------- --------------------------- --------------- --------------------------------------------- ------------------------- -----------
        **Additive Model**                                                                                                                                   
  19    rs838143             53943567    *FUT1*                      3′ UTR          A                                             0.05                      2.70 E-05
  5     rs2054440            150365152   *LOC134466* ∣ *GPX3*        Intergenic      G                                             0.42                      3.00 E-05
  19    rs838142             53943963    *FUT1*                      3′ UTR          T                                             0.25                      4.80 E-05
  5     rs17111637           150361436   *LOC134466* ∣ *GPX3*        Intergenic      A                                             0.35                      7.30 E-05
  3     rs12486347           70649298    *LOC100128160* ∣ *FOXP1*    Intergenic      A                                             0.14                      8.20 E-05
  14    rs2273844            24173254    *GZMB*                      5′ UTR          A                                             0.19                      8.20 E-05
  12    rs17539379           39414907    *CNTN1*                     Intron          A                                             0.08                      1.01 E-04
  19    rs4021               53945073    *FUT1*                      3′ UTR          G                                             0.25                      1.18 E-04
  19    rs463631             53926504    *RASIP1*                    Intron          A                                             0.04                      1.24 E-04
  19    rs392775             53931669    *RASIP1*                    Intron          T                                             0.04                      1.24 E-04
  5     rs6889028            55465663    *ANKRD55* ∣ *LOC727984*     Intergenic      A                                             0.03                      1.57 E-04
  22    rs135058             42168027    *MPPED1*                    Intron          T                                             0.05                      1.62 E-04
  5     rs2345000            150363456   *LOC134466* ∣ *GPX3*        Intergenic      A                                             0.34                      1.75 E-04
  14    rs9919930            39686800    *FBXO33* ∣ *LRFN5*          Intergenic      T                                             --                        1.83 E-04
  19    rs281384             53908738    *MAMSTR*                    Intron          A                                             0.02                      2.08 E-04
                                                                                                                                                             
        **Dominant Model**                                                                                                                                   
  3     rs9847915            161279884   *LOC730109* ∣ *BRD7P2*      Intergenic      A                                             0.29                      6.81 E-07
  11    rs118125355          35065834    *PDHX* ∣ *CD44*             Intergenic      --                                            0.01                      6.82 E-07
  1     rs4657067            159791329   *FCGR3A* ∣ *FCGR2C*         Intergenic      A                                             --                        1.15 E-06
  1     rs377982             159868496   *FCGR3B* ∣ *FCGR2B*         Intergenic      T                                             --                        1.15 E-06
  1     rs12735449           159785611   *FCGR3A*                    Intron          T                                             --                        1.36 E-06
  1     rs76158727           159865216   *FCGR3B*                    Intron          --                                            --                        1.36 E-06
  10    rs35980734           35301298    *PARD3* ∣ *CUL2*            Intergenic      G                                             0.33                      1.36 E-06
  1     rs111974271          159847992   *LOC1131982* ∣ *FCGR3B*     Intergenic      A                                             --                        1.93 E-06
  10    rs12251203           35479828    *CREM*                      Intron          G                                             0.40                      2.29 E-06
  11    rs9651751            70956476    *KRTAP5-10* ∣ *KRTAP5-11*   Intergenic      G                                             0.39                      2.45 E-06
  1     rs3964394            159803051   *FCGR3A* ∣ *FCGR2C*         Intergenic      --                                            --                        2.73 E-06
  1     rs143513265          151037507   *LCE1D* ∣ *LCE1C*           Intergenic      --                                            --                        3.16 E-06
  17    rs149259492          23182244    *NOS2A* ∣ *LOC201229*       Intergenic      --                                            0.35                      3.16 E-06
  16    rs762633             28515842    *SULT1A2*                   5′ UTR          C                                             0.33                      3.24 E-06
  10    rs4325270            60185474    *LOC728640* ∣ *BICC1*       Intergenic      A                                             0.55                      4.30 E-06

Minor allele was always used as the risk allele in the analysis

###### Adjusted Odds ratio (OR) for the top 15 SNPs associated with IVIG responsiveness using a) additive model and b) dominant model

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CHR                  SNP          Position    Gene Symbol                 Gene Location   Minor\   Odds Ratio-\         MAF-\        MAF\            MAF\     p-Value
                                                                                            allele   IVIG nonresponders   Responders   Nonresponders   HAPMAP   
  -------------------- ------------ ----------- --------------------------- --------------- -------- -------------------- ------------ --------------- -------- -----------
  **Additive Model**                                                                                                                                            

  14                   rs1200332    34436886    *BAZ1A* ∣ *C14orf19*        Intergenic      T        5.49                 0.13         0.33            0.21     1.40 E-04

  20                   rs6017164    41815520    *GTSF1L* ∣ *TOX2*           Intergenic      A        0.25                 0.45         0.32            0.45     1.95 E-04

  6                    rs4354185    110408354   *GPR6*                      3′ UTR          A        4.46                 0.25         0.43            0.48     2.74 E-04

  13                   rs7999399    88031506    *SLITRK5* ∣ *MIRH1*         Intergenic      C        3.42                 0.27         0.45            0.46     3.65 E-04

  6                    rs4317449    110408638   *GPR6* ∣ *WASF1*            Intergenic      T        4.22                 0.25         0.42            0.48     3.90 E-04

  6                    rs72945401   111833015   *REV3L*                     Intron          G        0.02                 0.14         0.02            0.12     5.82 E-04

  5                    rs10473594   22511857    *CDH12*                     Intron          C        4.51                 0.11         0.32            0.16     6.42 E-04

  2                    rs7579420    3938010     *LOC728597* ∣ *LOC727982*   Intergenic      T        0.31                 0.43         0.32            0.46     7.69 E-04

  15                   rs7163190    32812788    *GOLGA8B* ∣ *GJD2*          Intergenic      G        0.26                 0.33         0.18            0.29     8.66 E-04

  6                    rs3134926    32308125    *NOTCH4* ∣ *C6orf10*        Intergenic      C        0.27                 0.40         0.25            0.20     9.12 E-04

  6                    rs3777914    112011860   *TRAF3IP2*                  Intron          G        0.29                 0.50         0.32            0.47     9.40 E-04

  22                   rs16995211   33781639    *LARGE* ∣ *ISX*             Intergenic      A        5.69                 0.08         0.23            0.09     9.72 E-04

  4                    rs719379     40537658    *APBB2*                     Intron          T        3.46                 0.37         0.43            0.48     9.93 E-04

  6                    rs1883137    112013839   *TRAF3IP2*                  Intron          G        0.29                 0.47         0.34            0.46     9.98 E-04

  16                   rs11641163   79327374    *CDYL2*                     Intron          A        0.24                 0.43         0.37            0.47     1.07 E-03

                                                                                                                                                                

  **Dominant Model**                                                                                                                                            

  16                   rs4889606    30918684    *STX1B*                     Intron          G        0.13                 0.49         0.27            0.35     6.95 E-05

  16                   rs9926533    30921680    *STX1B*                     Intron          T        0.13                 0.49         0.27            0.35     6.95 E-05

  16                   rs4889603    30889726    *SETD1A*                    Intron          G        0.13                 0.50         0.29            0.38     8.79 E-05

  16                   rs12917722   30855898    *FBXL19*                    Intron          G        0.15                 0.50         0.29            0.42     1.57 E-04

  5                    rs10473594   22511857    *CDH12*                     Intron          C        5.82                 0.11         0.32            0.16     1.87 E-04

  14                   rs1200332    34436886    *BAZ1A* ∣ *C14orf19*        Intergenic      T        5.56                 0.13         0.33            0.21     2.25 E-04

  16                   rs8046707    30823734    *CTF1* ∣ *LOC283932*        Intergenic      A        0.18                 0.45         0.28            0.38     3.00 E-04

  16                   rs11649653   30825988    *CTF1* ∣ *LOC283932*        Intergenic      G        0.18                 0.45         0.28            0.38     3.00 E-04

  6                    rs4354185    110408354   *GPR6*                      3′ UTR          A        6.22                 0.25         0.43            0.48     3.09 E-04

  6                    rs3134926    32308125    *NOTCH4* ∣ *C6orf10*        Intergenic      C        0.16                 0.40         0.25            0.20     3.38 E-04

  16                   rs2288004    30961541    *STX4* ∣ *ZNF668*           Intergenic      C        0.17                 0.50         0.27            0.36     3.65 E-04

  16                   rs10871454   30955580    *STX4*                      Intron          T        0.17                 0.48         0.27            0.36     3.65 E-04

  16                   rs11150604   30944521    *STX1B* ∣ *STX4*            Intergenic      T        0.17                 0.48         0.27            0.36     3.65 E-04

  16                   rs12448321   30955781    *STX4*                      Intron          T        0.17                 0.48         0.27            0.36     3.65 E-04

  16                   rs9939417    30960968    *STX4* ∣ *ZNF668*           Intergenic      T        0.17                 0.48         0.27            0.36     3.65 E-04
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Replication of previous genome-wide associations with susceptibility to Kawasaki Disease

  CHR   SNP         Position   Gene Symbol          Gene Location   MAF HAPMAP   Model      p-Value
  ----- ----------- ---------- -------------------- --------------- ------------ ---------- ---------
  6     rs2857151   32871492   HLA-DQB2 ∣ HLA-DOB   Intergenic      0.44         Dominant   0.04
  20    rs4813003   44196691   CD40 ∣ CDH22         Intergenic      0.16         Dominant   0.04
